Gurugram, Haryana, India – (September 02, 2026) – DelveInsight’s “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Idiopathic Pulmonary Fibrosis Pipeline? @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight
Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report
- On August 31, 2026- Trevi Therapeutics initiated a study to evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis.
- On August 26, 2026- Contineum Therapeutics conducted a phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
- On August 24, 2026- AbbVie highlighted a study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time.
- DelveInsight’s Idiopathic Pulmonary Fibrosis Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
- The leading Idiopathic Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
- Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.
Want to know which companies are leading innovation in Idiopathic Pulmonary Fibrosis? @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment
The Idiopathic Pulmonary Fibrosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Idiopathic Pulmonary Fibrosis Pipeline Report also highlights the unmet needs with respect to the Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).
Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
- BMS-986278: Bristol-Myers Squibb
Admilparant (BMS-986278) is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA1 are involved in the pathogenesis of pulmonary fibrosis. A preclinical in vitro and in vivo study found that antagonizing LPA1 may be beneficial in treating lung injury and fibrosis. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.
- ENV-101: Endeavor BioMedicine
ENV-101 (Endeavor BioMedicine) is an investigational small-molecule therapy being developed by Endeavor BioMedicine for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It is designed to selectively inhibit pathways involved in fibrosis progression, aiming to reduce excessive tissue scarring and preserve lung function. The drug is currently in early clinical development, with studies focused on evaluating its safety, tolerability, and anti-fibrotic activity. Preclinical findings have shown potential to modulate key drivers of fibrosis, supporting its advancement into human trials. Overall, ENV-101 represents a targeted approach that could offer improved disease control compared to existing symptomatic treatments for fibrotic lung disorders. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.
- AZD8965: AstraZeneca
AZD8965 (AstraZeneca) is an investigational small-molecule therapy being developed by AstraZeneca for idiopathic pulmonary fibrosis (IPF). It functions as an arginase (ARG1/ARG2) inhibitor, targeting metabolic pathways linked to fibrosis progression. The drug is currently in Phase I clinical development, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy participants. By modulating arginase activity, AZD8965 aims to reduce fibrotic remodeling and inflammation, representing a novel mechanism compared to existing IPF therapies. If successful, it could provide a new targeted treatment approach for fibrotic lung diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.
If you’re tracking ongoing Idiopathic Pulmonary Fibrosis Clinical trials, this press release is a must-read @ Idiopathic Pulmonary Fibrosis Treatment Drugs
The Idiopathic Pulmonary Fibrosis Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
- Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.
Idiopathic Pulmonary Fibrosis Companies
Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
Idiopathic Pulmonary Fibrosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as,
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
The Idiopathic Pulmonary Fibrosis Pipeline Report covers it all @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
- Coverage- Global
- Idiopathic Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
- Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.
- Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what’s next for the Idiopathic Pulmonary Fibrosis Treatment landscape in this detailed analysis @ Idiopathic Pulmonary Fibrosis Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Idiopathic Pulmonary Fibrosis: Overview
- Pipeline Therapeutics
- Therapeutics Assessment
- Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- BMS-986278: Bristol-Myers Squibb
- Mid Stage Products (Phase II)
- ENV-101: Endeavor BioMedicine
- Early Stage Products (Phase I)
- AZD8965 AstraZeneca
- Preclinical and Discovery Stage Products
- Inactive Products
- Idiopathic Pulmonary Fibrosis Key Companies
- Idiopathic Pulmonary Fibrosis Key Products
- Idiopathic Pulmonary Fibrosis- Unmet Needs
- Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
- Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
- Idiopathic Pulmonary Fibrosis Analyst Views
- Idiopathic Pulmonary Fibrosis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight